Boston Scientific has announced today that it has received FDA approval to market its TAXUS® Liberte® Long Paclitaxel-Eluting Coronary Stent System, a 38mm long device. The stent is marketed as the longest drug-eluting stent currently available on the market. Whereas previously for extra-long lesions in coronary vessels clinicians would have to piggy-back to shorter stents together, one stent can now be used.
From the press release:
“The TAXUS Liberte Long Stent offers physicians and patients distinct advantages compared to using two overlapping drug-eluting stents,” said Mark Turco, M.D., FACC, FSCAI, Director of the Center for Cardiac Vascular Research at Washington Adventist Hospital, Takoma Park, Maryland. “In the ATLAS Long Lesion Trial, the 38 mm TAXUS Liberte Stent significantly reduced myocardial infarction when compared to the TAXUS(R) Express(R) Stent, making the TAXUS Liberte Long Stent an attractive option for interventional cardiologists faced with long, challenging lesions.”
Read the press release here…